000277139 001__ 277139
000277139 005__ 20240229155012.0
000277139 0247_ $$2doi$$a10.3390/cancers15123092
000277139 0247_ $$2pmid$$apmid:37370702
000277139 0247_ $$2altmetric$$aaltmetric:151013988
000277139 037__ $$aDKFZ-2023-01301
000277139 041__ $$aEnglish
000277139 082__ $$a610
000277139 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000277139 245__ $$aPopulation-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers.
000277139 260__ $$aBasel$$bMDPI$$c2023
000277139 3367_ $$2DRIVER$$aarticle
000277139 3367_ $$2DataCite$$aOutput Types/Journal article
000277139 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1688023575_6926
000277139 3367_ $$2BibTeX$$aARTICLE
000277139 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277139 3367_ $$00$$2EndNote$$aJournal Article
000277139 500__ $$a#EA:C020#
000277139 520__ $$aWe aim to estimate population-attributable fractions (PAF) for 13 comorbidities potentially predisposing to hepatobiliary cancer of hepatocellular carcinoma (HCC), gallbladder cancer (GBC), cancers of the intrahepatic and extrahepatic bile ducts (ICC and ECC), and ampullary cancer.Patients were identified from the Swedish Inpatient Register from 1987 to 2018 and cancers from the Swedish Cancer Registry from 1997 through 2018. PAFs were calculated for each comorbidity-associated cancer using a cohort study design.For male HCC, the major individual comorbidities (PAF > 10) were diabetes, alcohol-related liver disease, and hepatitis C virus infection. For female HCC, diabetes and autoimmune diseases were important contributors. For female GBC, gallstone disease was an overwhelming contributor, with a PAF of 30.57%, which was also important for men. The overall PAF for male ICC was almost two times higher than the female one. For ECC and ampullary cancer, infection of bile ducts was associated with the highest PAF.The 13 comorbidities accounted for 50% or more of the potential etiological pathways of each hepatobiliary cancer except female ICC. The underlying convergent mechanism for these cancers may be chronic inflammation lasting for decades and thus offering possibilities for intervention and disease monitoring.
000277139 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000277139 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277139 650_7 $$2Other$$aalcohol
000277139 650_7 $$2Other$$abile duct infection
000277139 650_7 $$2Other$$acomorbidity
000277139 650_7 $$2Other$$ahepatocellular carcinoma
000277139 650_7 $$2Other$$arisk factor
000277139 650_7 $$2Other$$aviral infection
000277139 7001_ $$aSundquist, Kristina$$b1
000277139 7001_ $$aSundquist, Jan$$b2
000277139 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b3$$udkfz
000277139 7001_ $$aLiska, Vaclav$$b4
000277139 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b5
000277139 7001_ $$00000-0002-5559-4657$$aLi, Xinjun$$b6
000277139 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15123092$$gVol. 15, no. 12, p. 3092 -$$n12$$p3092$$tCancers$$v15$$x2072-6694$$y2023
000277139 909CO $$ooai:inrepo02.dkfz.de:277139$$pVDB
000277139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000277139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000277139 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000277139 9141_ $$y2023
000277139 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-24T07:56:58Z
000277139 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000277139 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000277139 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000277139 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000277139 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000277139 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000277139 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000277139 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000277139 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000277139 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000277139 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000277139 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000277139 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000277139 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000277139 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000277139 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000277139 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000277139 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000277139 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000277139 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000277139 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000277139 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000277139 980__ $$ajournal
000277139 980__ $$aVDB
000277139 980__ $$aI:(DE-He78)C020-20160331
000277139 980__ $$aI:(DE-He78)B062-20160331
000277139 980__ $$aI:(DE-He78)HD01-20160331
000277139 980__ $$aUNRESTRICTED